| Literature DB >> 24688879 |
Abstract
In low- and middle-income countries, the attrition across the continuum of care of HIV infected children is not well known. The aim of this study was to investigate predictors of mortality and loss to follow up (LTFU) in HIV infected children from a cohort study in India and to describe the cascade of care from HIV diagnosis to virological suppression after antiretroviral therapy (ART) initiation. Multivariable analysis was performed using competing risk regression. The cumulative incidence of attrition due to mortality or LTFU after five year of follow-up was 16% from entry into care to ART initiation and 24.9% after ART initiation. Of all children diagnosed with HIV, it was estimated that 91.9% entered into care, 77.2% were retained until ART initiation, 58% stayed in care after ART initiation, and 43.4% achieved virological suppression on ART. Approximately half of the attrition occurred before ART initiation, and the other half after starting ART. Belonging to socially disadvantaged communities and living >90 min from the hospital were associated with a higher risk of attrition. Being >10 years old and having higher 12-month risk of AIDS (calculated using the absolute CD4 lymphocyte count and the age) were associated with an increased risk of mortality. These findings indicate that we should consider placing more emphasis on promoting research and implementing interventions to improve the engagement of HIV infected children in pre-ART care. The results of this study can be used by HIV programmes to design interventions aimed at reducing the attrition across the continuum of care of HIV infected children in India.Entities:
Keywords: Antiretroviral therapy highly active; HIV; India; Lost to follow-up; Mortality; Pediatrics; Rural; Viral load
Year: 2014 PMID: 24688879 PMCID: PMC3961166 DOI: 10.7717/peerj.304
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Flowchart of HIV infected children during the continuum of care.
Baseline characteristics, univariate and multivariable analysis of factors associated with antiretroviral therapy (ART) initiation, mortality and loss to follow up before ART initiation.
| ART initiation | Mortality | Loss to follow up | |||||
|---|---|---|---|---|---|---|---|
| N (%) | SHR | aSHR | SHR | aSHR | SHR | aSHR | |
|
| |||||||
| 0–2 | 116 (24.47) | 2.32 | 1.69 | 2.54 (0.51–12.74) | 1.23 (0.08–17.88) | 0.58 (0.25–1.31) | 0.77 (0.32–1.85) |
| 3–4 | 99 (20.89) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 5–9 | 176 (37.13) | 1.32 (0.94–1.86) | 1.35 (0.95–1.93) | 1.07 (0.20–5.72) | 1.17 (0.14–9.40) | 0.91 (0.47–1.75) | 0.87 (0.41–1.81) |
| >=10 | 83 (17.51) | 2.22 | 2.09 | 0.57 (0.05–6.28) | 0.99 (0.06–15.38) | 0.73 (0.31–1.68) | 0.71 (0.29–1.73) |
|
| |||||||
| Female | 236 (49.58) | 0.85 (0.68–1.07) | 0.89 (0.70–1.14) | 2.33 (0.72–7.59) | 2.86 (0.62–13.22) | 0.77 (0.46–1.30) | 0.74 (0.43–1.28) |
| Male | 240 (50.42) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
|
| |||||||
| OC | 97 (20.38) | 1.22 (0.93–1.61) | 1.26 (0.96–1.67) | 1.29 (0.23–7.06) | 0.89 (0.10–8.18) | 0.80 (0.38–1.70) | 0.79 (0.36–1.74) |
| BC | 249 (52.31) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| SC | 104 (21.85) | 1.01 (0.74–1.40) | 1.06 (0.76–1.48) | 3.73 | 4.87 | 1.15 (0.60–2.23) | 1.16 (0.56–2.40) |
| ST | 26 (5.46) | 0.43 | 0.42 | 2.46 (0.28–21.35) | 2.76 (0.18–42.03) | 2.59 | 2.80 |
|
| |||||||
| No | 297 (62.39) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Yes | 179 (37.61) | 0.83 (0.65–1.06) | 0.85 (0.66–1.11) | 0.28 (0.07–1.24) | 0.29 (0.06–1.39) | 1.50 (0.89–2.52) | 1.58 (0.86–2.89) |
|
| |||||||
| <30 min | 132 (27.73) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 30–59 min | 91 (19.12) | 1.25 (0.88–1.77) | 1.18 (0.82–1.70) | 0.59 (0.12–3.04) | 0.41 (0.04–3.87) | 1.25 (0.54–2.90) | 1.65 (0.67–4.06) |
| 60–90 min | 108 (22.69) | 1.05 (0.75–1.48) | 1.07 (0.75–1.53) | 0.74 (0.18–3.12) | 0.42 (0.09–2.01) | 1.58 (0.74–3.40) | 1.55 (0.67–3.59) |
| >90 min | 135 (30.46) | 1.21 (0.89–1.66) | 1.15 (0.82–1.59) | 0.53 (0.13–2.19) | 0.41 (0.07–2.55) | 1.53 (0.75–3.13) | 1.87 (0.90–3.89) |
|
| |||||||
| 2007 | 81 (17.09) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2008 | 83 (17.51) | 0.79 (0.57–1.09) | 0.81 (0.57–1.14) | 5.43 (0.74–39.81) | 5.69 (0.64–50.47) | 0.38 (0.12–1.19) | 0.41 (0.13–1.30) |
| 2009 | 96 (20.25) | 0.65 | 0.70 (0.48–1.03) | 0.91 (0.06–12.90) | 1.06 (0.05–23.39) | 1.12 (0.49–2.54) | 1.20 (0.51–2.81) |
| 2010 | 93 (19.62) | 0.62 | 0.73 (0.49–1.08) | 1.93 (0.20–18.32) | 1.42 (0.12–17.04) | 1.46 (0.68–3.15) | 1.53 (0.69–3.37) |
| 2011 | 56 (11.81) | 0.61 | 0.61 | 3.46 (0.37–32.57) | 4.46 (0.39–50.94) | 1.28 (0.51–3.20) | 1.46 (0.57–3.75) |
| 2012 | 65 (13.71) | 0.63 | 0.58 | 3.26 (0.34–31.19) | 3.84 (0.20–74.86) | 0.90 (0.33–2.45) | 1.12 (0.40–3.14) |
|
| |||||||
| Alive, rented house | 138 (28.99) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Alive, owned house | 113 (23.74) | 1.10 (0.78–1.55) | 1.25 (0.86–1.81) | 0.65 (0.16–2.60) | 0.43 (0.06–3.21) | 0.51 (0.24–1.06) | 0.48 (0.23–1.02) |
| Father died | 115 (24.16) | 1.37 (1.00–1.88) | 1.62 | 0.20 (0.02–1.65) | 0.15 (0.01–1.56) | 0.57 (0.28–1.14) | 0.50 (0.25–1.00) |
| Mother died | 47 (9.87) | 1.66 | 1.99 | 0.49 (0.06–4.02) | 0.32 (0.03–3.17) | 0.59 (0.23–1.54) | 0.68 (0.25–1.87) |
| Both died | 63 (13.24) | 1.76 | 1.88 | 0.69 (0.15–3.23) | 0.80 (0.11–5.86) | 0.50 (0.21–1.21) | 0.48 (0.20–1.19) |
|
| 3.8 (3.2–8.7) | 1.03 | 1.03 | 1.04 | 1.05 | 0.98 (0.93–1.02) | 0.98 (0.94–1.03) |
Notes.
P-value <0.05.
Median (interquartile range).
adjusted sub-distribution hazard ratio
antiretroviral therapy
backward castes
confidence interval
number
other castes
sub-distribution hazard ratio
scheduled castes
scheduled tribes
Figure 2Cumulative incidence of antiretroviral therapy (ART) initiation and attrition (mortality or loss to follow up) after engagement in care of 476 HIV infected children in Anantapur, India.
Baseline characteristics, univariate and multivariate analysis of factors associated with mortality and loss to follow up after antiretroviral therapy initiation.
| Mortality | Loss to follow up | ||||
|---|---|---|---|---|---|
| N (%) | SHR | aSHR | SHR | aSHR | |
|
| |||||
| 0–1 | 45 (16.01) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2–4 | 61 (21.71) | 0.45 (0.14–1.43) | 1.52 (0.28–8.28) | 1.03 (0.34–3.10) | 0.98 (0.21–4.56) |
| 5–9 | 99 (35.23) | 0.18 | 0.73 (0.11–5.11) | 0.94 (0.32–2.77) | 1.33 (0.29–5.98) |
| >=10 | 76 (27.05) | 1.01 (0.38–2.69) | 5.30 | 0.65 (0.18–2.27) | 0.93 (0.16–5.32) |
|
| |||||
| Female | 131 (46.62) | 0.83 (0.38–1.80) | 0.91 (0.37–2.24) | 0.62 (0.29–1.34) | 0.66 (0.27–1.60) |
| Male | 150 (53.38) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
|
| |||||
| OC | 67 (23.84) | 0.99 (0.38–2.62) | 0.67 (0.23–1.97) | 0.65 (0.24–1.75) | 0.82 (0.29–2.37) |
| BC | 149 (53.02) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| SC | 57 (20.28) | 1.46 (0.57–3.72) | 0.85 (0.21–3.49) | 1.18 (0.49–2.86) | 1.13 (0.32–4.05) |
| ST | 8 (2.85) | 1.27 (0.18–8.76) | 0.67 (0.12–3.85) | 1.00 (0.12–8.36) | 1.07 (0.09–13.25) |
|
| |||||
| No | 181 (64.41) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Yes | 100 (35.59) | 1.24 (0.56–2.73) | 1.09 (0.37–3.20) | 1.07 (0.50–2.30) | 1.52 (0.61–3.77) |
|
| |||||
| <30 min | 72 (25.62) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 30–59 min | 55 (19.57) | 1.93 (0.68–5.46) | 2.55 (0.71–9.14) | 0.75 (0.18–3.17) | 1.04 (0.22–4.82) |
| 60–90 min | 62 (22.06) | 1.23 (0.39–3.83) | 0.84 (0.19–3.79) | 0.51 (0.10–2.61) | 0.71 (0.12–4.27) |
| >90 min | 92 (32.74) | 0.64 (0.19–2.13) | 0.82 (0.20–3.26) | 3.17 | 5.07 |
|
| |||||
| 2007 | 36 (12.81) | 0.93 (0.08–11.20) | 0.62 (0.03–12.75) | 0.31 (0.08–1.17) | 0.38 (0.07–2.07) |
| 2008 | 44 (15.66) | 3.53 (0.41–30.52) | 5.04 (0.43–58.87) | 0.42 (0.11–1.64) | 0.62 (0.12–3.17) |
| 2009 | 54 (19.22) | 2.26 (0.25–20.47) | 2.64 (0.19–36.41) | 0.61 (0.17–2.13) | 0.77 (0.14–4.31) |
| 2010 | 59 (21) | 2.59 (0.28–23.54) | 2.90 (0.18–46.20) | 0.47 (0.13–1.69) | 0.65 (0.14–3.12) |
| 2011 | 39 (13.88) | 3.17 (0.32–31.12) | 2.60 (0.13–51.85) | 0.33 (0.06–1.81) | 0.40 (0.05–3.08) |
| 2012 | 49 (17.44) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
|
| |||||
| Alive, rented house | 73 (25.98) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Alive, owned house | 60 (21.35) | 1.49 (0.50–4.43) | 0.89 (0.23–3.47) | 2.27 (0.86–5.96) | 2.38 (0.87–6.52) |
| Father died | 73 (25.98) | 0.83 (0.25–2.76) | 0.62 (0.11–3.37) | 1.03 (0.33–3.18) | 1.13 (0.32–3.96) |
| Mother died | 29 (10.32) | 0.39 (0.05–3.19) | 0.50 (0.06–4.53) | 0.41 (0.05–3.38) | 0.34 (0.04–2.89) |
| Both died | 46 (16.37) | 1.81 (0.61–5.39) | 1.72 (0.34–8.76) | 1.29 (0.40–4.16) | 0.83 (0.20–3.35) |
|
| |||||
| <3 months | 152 (54.48) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| >3 months | 127 (45.52) | 0.42 (0.17–1.07) | 0.36 | 0.44 (0.18–1.04) | 0.42 (0.15–1.21) |
|
| 4.9 (3.4–12.5) | 1.04 | 1.04 | 1.00 (0.98–1.03) | 1.00 (0.97–1.04) |
Notes.
P-value <0.05
median (interquartile range).
adjusted sub-distribution hazard ratio
antiretroviral therapy
backward castes
confidence interval
number
other castes
sub-distribution hazard ratio
scheduled castes
scheduled tribes
Figure 3Cumulative incidence of mortality and loss to follow up after antiretroviral therapy (ART) initiation of 281 HIV infected children in Anantapur, India.
Figure 4Cumulative incidence of mortality and loss to follow up after engagement in care of 476 HIV infected children in Anantapur, India.
Univariate and multivariate analysis of factors associated with mortality and loss to follow up after engagement in care of 476 HIV-infected children in Anantapur, India.
| Mortality | Loss to follow up | |||
|---|---|---|---|---|
| SHR | aSHR | SHR | aSHR | |
|
| ||||
| 0–2 | 7.23 | 1.95 (0.29–12.92) | 0.74 (0.40–1.39) | 0.83 (0.42–1.65) |
| 3–4 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 5–9 | 2.23 (0.47–10.57) | 1.66 (0.32–8.53) | 0.79 (0.46–1.37) | 0.77 (0.42–1.42) |
| > =10 | 7.02 | 7.26 | 0.80 (0.41–1.57) | 0.80 (0.39–1.64) |
|
| ||||
| Female | 1.08 (0.58–2.02) | 1.44 (0.69–3.03) | 0.69 (0.45–1.06) | 0.66 (0.42–1.04) |
| Male | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
|
| ||||
| OC | 1.21 (0.52–2.83) | 1.00 (0.38–2.61) | 0.76 (0.42–1.38) | 0.78 (0.43–1.43) |
| BC | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| SC | 2.01 (0.96–4.20) | 2.65 | 1.12 (0.66–1.91) | 1.24 (0.70–2.20) |
| ST | 1.14 (0.27–4.79) | 1.52 (0.39–5.95) | 1.85 (0.87–3.95) | 2.34 |
|
| ||||
| No | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Yes | 0.72 (0.37–1.43) | 0.78 (0.36–1.67) | 1.30 (0.84–1.99) | 1.52 (0.95–2.44) |
|
| ||||
| <30 min | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 30–59 min | 1.46 (0.63–3.35) | 1.30 (0.49–3.46) | 1.13 (0.54–2.35) | 1.35 (0.62–2.94) |
| 60–90 min | 1.03 (0.43–2.49) | 0.82 (0.31–2.16) | 1.31 (0.67–2.59) | 1.32 (0.64–2.70) |
| >90 min | 0.65 (0.26–1.62) | 0.67 (0.25–1.83) | 2.15 | 2.48 |
|
| ||||
| 2007 | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| 2008 | 4.46 | 8.03 | 0.63 (0.28–1.41) | 0.69 (0.30–1.59) |
| 2009 | 2.65 (0.90–7.80) | 3.95 | 1.38 (0.72–2.65) | 1.55 (0.78–3.08) |
| 2010 | 1.74 (0.52–5.87) | 2.67 (0.72–9.89) | 1.69 (0.89–3.20) | 1.82 (0.94–3.53) |
| 2011 | 4.39 | 5.35 | 1.37 (0.61–3.08) | 1.46 (0.64–3.36) |
| 2012 | 1.72 (0.34–8.83) | 1.05 (0.09–12.74) | 1.89 (0.84–4.26) | 2.01 (0.85–4.78) |
|
| ||||
| Alive, rented house | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Alive, owned house | 1.12 (0.48–2.63) | 1.18 (0.39–3.53) | 0.87 (0.50–1.53) | 0.83 (0.47–1.47) |
| Father died | 0.60 (0.22–1.60) | 0.58 (0.16–2.09) | 0.72 (0.40–1.29) | 0.66 (0.36–1.20) |
| Mother died | 0.50 (0.11–2.21) | 0.51 (0.10–2.49) | 0.59 (0.25–1.42) | 0.64 (0.26–1.58) |
| Both died | 1.62 (0.69–3.79) | 1.96 (0.64–6.02) | 0.76 (0.38–1.49) | 0.71 (0.34–1.49) |
|
| 1.05 | 1.07 | 1.00 (0.98–1.02) | 1.00 (0.98–1.02) |
Notes.
P-value <0.05.
median (interquartile range).
adjusted sub-distribution hazard ratio
antiretroviral therapy
backward castes
confidence interval
number
other castes
sub-distribution hazard ratio
scheduled castes
scheduled tribes
Summary of the cumulative incidence of antiretroviral therapy (ART) initiation, and attrition due to mortality and lost to follow up (LTFU) of HIV infected children from Anantapur, India.
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
|
| 32.8 (28.6–37) | 38.7 (34.3–43.1) | 48.5 (43.9–52.9) | 55.5 (50.9–59.9) | 59.2 (54.6–63.7) | 61.5 (56.7–65.9) | 63.4 (58.3–68.1) |
|
| 5.7 (3.8–8) | 7.4 (5.2–10) | 9.5 (7.1–12.3) | 12.1 (9.3–15.2) | 14.7 (11.6–18.2) | 15.5 (12.3–19.1) | 16 (12.6–19.7) |
| Mortality | 0.8 (0.3–2) | 0.8 (0.3–2) | 1.7 (0.8–3.2) | 2.2 (1.1–3.8) | 2.7 (1.5–4.6) | 2.7 (1.5–4.6) | 2.7 (1.5–4.6) |
| LTFU | 4.8 (3.2–7) | 6.5 (4.5–9) | 7.8 (5.6–10.4) | 9.9 (7.4–12.9) | 12 (9.2–15.3) | 12.8 (9.8–16.2) | 13.3 (10.2–16.8) |
|
| 4.3 (2.5–7.5) | 6.9 (4.5–10.6) | 9.5 (6.6–13.7) | 15.1 (11.3–20.2) | 18.3 (13.9–23.8) | 19.8 (15.1–25.8) | 24.9 (18.7–32.7) |
| Mortality | 2.5 (1.1–4.9) | 4 (2–6.8) | 4.4 (2.4–7.3) | 7.8 (4.9–11.5) | 9.3 (6–13.3) | 9.3 (6–13.3) | 13.2 (8.2–19.3) |
| LTFU | 1.8 (0.7–3.9) | 2.9 (1.4–5.4) | 5.2 (3–8.3) | 7.3 (4.6–10.9) | 9 (5.8–13.1) | 10.6 (6.8–15.2) | 11.7 (7.5–16.9) |
|
| 7.6 (5.5–10.4) | 10.8 (8.3–13.9) | 14.2 (11.4–17.7) | 20.1 (16.7–24.1) | 25.3 (21.4–29.7) | 26.4 (22.4–31) | 29 (24.6–33.9) |
| Mortality | 1.9 (0.9–3.4) | 2.5 (1.4–4.2) | 4 (2.5–6.1) | 6.2 (4.2–8.6) | 8 (5.7–10.8) | 8 (5.7–10.8) | 9.1 (6.5–12.4) |
| LTFU | 5.7 (3.8–8) | 8.2 (6–10.9) | 10.2 (7.6–13.1) | 14 (11–17.3) | 17.3 (13.9–21) | 18.4 (14.8–22.3) | 19.8 (16–24) |
Figure 5Cumulative retention of children at each stage of care after HIV diagnosis.